Protalix BioTherapeutics (PLX) Commences Dosing of PRX-102 Phase 3 for Fabry Disease
- Wall Street dips as investors ready for Trump's inauguration
- Western Union (WU) Admits Anti-Money Laundering and Consumer Fraud Violations, Forfeits $586M in Settlement
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- Apple (AAPL) PT Raised to $140 at BofA/Merrill Lynch; iPhone 8 Will be 'Super-Long' Cycle
- Morgan Stanley Upgrades Tesla Motors (TSLA) to Overweight
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced that the first patient has been dosed in its global phase III clinical trial of PRX-102 for the treatment of Fabry disease. There are currently six of the leading Fabry centers activated and participating in the trial, with up to an additional 21 centers, currently in different initiation processes, that are expected to be opened before year end.
“The phase III Fabry trial is extremely important to the Company and remains a major focus for our team. We are pleased to announce the first patient has been infused, a milestone we have been working towards,” said Mr. Moshe Manor, Protalix’s President and Chief Executive Officer. “Interest from the physician and patient community in the trial is high, and a number of patients have already gone through the screening process. The trial has certain stringent inclusion criteria in place to maximize the likelihood of demonstrating superiority. Once all the anticipated trial sites are up and running, which we anticipate completing around year end, we will provide guidance regarding expected enrollment completion.”
The phase III efficacy and safety clinical trial, which we refer to as the BALANCE Study, is a 24-month multi-center, randomized, double-blind, active control study of PRX-102 for the treatment of Fabry disease in Fabry patients with impaired renal function. The trial is designed to enroll 78 patients previously treated with Fabrazyme® (agalsidase beta) with a stable dose for at least six months. Enrolled patients will be randomized to continue treatment with 1 mg/kg of either Fabrazyme or PRX-102, at a 2:1 ratio of PRX-102 to Fabrazyme, respectively. Patients are to be treated via intravenous (IV) infusions every two weeks.
The sites are recruiting adult symptomatic Fabry patients with plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than 30% mean normal levels. All patients must have had treatment with a dose of 1 mg/kg agalsidase beta per infusion every two weeks for at least one year. In addition, to be included in the trial, patients need to have certain eGFR values and a meaningful decline in annualize eGFR slope.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransCanada (TRP) Announces Receipt of FERC Approval to Construct Leach XPress, Rayne XPress Projects
- Allergan (AGN) Announces FDA Approval Of RHOFADE Cream to Treat Redness Associated with Rosacea
- AbbVie (ABBV) Announces FDA Approval for IMBRUVICA to Treat Specifically Indicated for R/R MZL
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!